FDA approval - TAK top pharma firm in Asia, top 9 globally has yet proven strong
Maribavir will be the first and only treatment indicated for adults in this patient population, expected net profit value at amazing $1.118B
$Takeda Pharmaceutical (TAK.US)$
CMV is a beta herpes virus that commonly affects individuals who have compromised immune systems. Out of the approximately 200,000 adult transplants per year worldwide, CMV is one of the most common viral infections. It has an estimated incidence rate of between 16% and 56% in solid organ transplant recipients and 30% to 70% percent in hematopoietic stem cell transplant patients.
$Takeda Pharmaceutical (TAK.US)$
CMV is a beta herpes virus that commonly affects individuals who have compromised immune systems. Out of the approximately 200,000 adult transplants per year worldwide, CMV is one of the most common viral infections. It has an estimated incidence rate of between 16% and 56% in solid organ transplant recipients and 30% to 70% percent in hematopoietic stem cell transplant patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
